![]() |
|
|
Vol. 299, Issue 1, 198-203, October 2001
Division of Pulmonary and Critical Care Medicine, University of
Michigan Medical Center, Ann Arbor, Michigan
We have previously shown that the ability of overnight pretreatment
with lipopolysaccharide (LPS) to suppress alveolar macrophage (AM)
leukotrienes (LT) synthesis is explained by induction of nitric oxide
(NO), and reactive oxygen intermediates (ROI). More recently we have
demonstrated that the generation of peroxynitrite (ONOO
)
from the combination of NO and ROI directly nitrotyrosinates the
5-lipoxygenase (5-LO) enzyme and reduces cell-free and intact AM 5-LO
metabolism. This effect of ONOO
was associated with
nitrotyrosination of the 5-LO enzyme in intact cells and after
treatment of recombinant enzyme. We postulated that LPS treatment of
cells resulted in activation of 5-LO with the generation of ROI, which
in turn led to autoinactivation of the enzyme. In an effort to suppress
ROI generated from activation of 5-LO we examined the effect of a
direct 5-LO inhibitor on LPS-induced suppression of LT synthesis.
Coincubation with the reversible 5-LO inhibitor zileuton during the LPS
pretreatment of intact cells dose dependently blocked the inhibition of
5-LO metabolism by LPS. The effect of zileuton on LPS-induced
suppression of LT synthesis was similar to that of
N-monomethyl-L-arginine. Zileuton had
no effect on inducible nitric-oxide synthase induction. Interestingly, zileuton blocked ONOO
-induced nitrotyrosination of
recombinant 5-LO in a cell-free system as well as of native enzyme in
intact cells. Moreover, zileuton blocked the nitrotyrosination of other
proteins. We conclude that the suppression of 5-LO activity occurring
with LPS treatment can be blocked by zileuton. The mechanism by which
zileuton is effective is in part explained by blocking
nitrotyrosination of 5-LO.